# Bioinformatics for Biochemistry and Molecular Biology

Hsueh-Fen Juan (阮雪芬) 05/20/2010

Email: yukijuan@ntu.edu.tw

生物分析化學

# Outline

- Introduction
- Construction of gene/protein network
- Drug Discovery
- Mechanism study

# Introduction

# **Systems Biology**

- **Definition**: Quantitative study of biological processes as whole systems instead of isolate parts.
- Goal: Construction and experimental validation of models that explain and predict the behavior of biological systems -2001, 2nd International Conference on Systems Biology

### Why Do We Need Systems Biology?

- The map of the genome is just the rule book;
   "systems biology" is the ball game.
  - by Alexandra Stikeman, Technology Review, 2002
     March









# Recent Developments of Systems Biology in US


- In 2003, MIT received a 5-year 16 million research grant from National Institute of Health to study systems biology.
- Harvard University created "Department of Systems Biology" in 2003.


# Traditional Biology & Systems Biology


- Traditional biology :
  - Single gene or protein
- Systems biology:
  - Simultaneously study the complex interaction of many levels of biological information to understand how they work together





# The Evolution of Molecular Biology into Systems Biology













# Traditional and Current Biology

- Traditionally, biology has been an observational science.
- Now, biology has been converted into deductive science.

# The Data of Bioinformatics

- Very very large amount
- Nucleotide sequence databanks contain 1.7 x 10<sup>12</sup> bases
- The full three-dimensional coordinates of proteins of average length ~400 residues > 50000 entries
- Not only are the individual databanks large, but their sizes are increasing as a very high rate.





# The History

- Sequence database began in the early 1960s, when Margaret Dayhoff and colleagues at the Protein Information Resource (PIR) collected all of the protein sequences known at that time.
- Atlase of Protein Sequence and Structure





PIR: http://pir.georgetown.edu/


# The History


 The advent of DNA sequence databases in 1982, initiated by the European Molecular Biology Laboratory (EMBL) and joined shortly thereafter by GenBank, led to the next phase in the history of sequence databases













### **DDBJ**

Joined the data-collecting collaboration a few years later



# International Nucleotide Sequence Database Collaboration

- In 1988, there was an agreement to use a common format for data elements within a unit record and to have each database update only the records that were directly submitted to it.
- DDBJ/EMBL/GenBank records are updated automatically every 24 hours at all these sites.



# First Protein Sequence Database


• In 1980s, Swiss-Prot Protein Sequence Database was laid.




# Tremble: Translation of EMBL nucleotide sequences | Continue | Co

# Goals

- "Saw life clearly and saw it whole"
  - Understand integrative aspects of the biology of organisms
- To interrelate sequence, three-dimensional structure, interactions, and function of individual proteins, nucleic acids and proteinnucleic acid complexes






# Protein-Protein Interactions & Biological Pathways

• Kanehisa (2000):

Interaction → Network → Function

Post-genome informatics (2000)




# **Protein-Protein Interactions**

- Protein-protein interactions are intrinsic to every cellular process.
- Form the basis of phenomena
  - DNA replication and transcription
  - Metabolism
  - Signal transduction
  - Cell cycle control
  - Secretion


# Construction of Gene/protein Network

- Electrophoresis (2002) 23: 2490 -2504.
- Bioinformatics (2004) **20**: 3691-3693.
- Proteomics (2006) **6**, 2991-3000.



# **Cancer Robustness**

 Viewing cancer as a robust system with potential points of fragility opens up new strategies for the development of drugs and therapies.




NATURE 2003, 426, 125.


Hunt for fragility: weaknesses in tumor growth dynamics could yield new anti-cancer therapies.

# Structure of Integrin


 Hynes in 1987 to emphasize the role of these RGD receptors in integrating the extracellular matrix outside the cell with the actin-containing cytoskeleton inside the cell.





# Interactions of Integrins w/ Other Proteins





 Signal are presumably transmitted into the nucleus, where they stimulate the transcription of gene involved in cell growth and proliferation






















		Pro	tein Ide	entitic	cation		
Up-regulated proteins		Down-regulated proteins					
6T-l <sup>41</sup>	MKSTYX	6C-1 <sup>51</sup>	Dt.T	48C-3 <sup>(1)</sup>	RYRI	72C-15 <sup>Q</sup>	PRX
6T-2 <sup>b)</sup>	CFI.2	6C-2 <sup>51</sup>	GAPD	48C-4 <sup>lo</sup>	IINR?A2BI	72C-19 <sup>10</sup>	NF2
6T-4 <sup>b</sup> '	HSPA8	6C-3"	ZFP161	48C-5 <sup>lo</sup>	VDAC	72C-20 <sup>t)</sup>	ACTGI
6T-5 <sup>by</sup>	CFL2	6C-4 <sup>a)</sup>	DDX21	48C-6 <sup>kg</sup>	HNR2A2B1		
61.9 <sub>00</sub>	PANKI	6C-5 <sup>51</sup>	PPIA	48C-8"	DUT		
6T-7"	IISD11B2	6C-631	PPIA	72C-1 <sup>hs</sup>	HNR2A2B1		
24T-1 <sup>29</sup>	PSCA TUBA6	24C-2**)	ARFI21	72C-2 <sup>kg</sup>	HNR2A2B1		
24T-8"	1.4	24C-3 <sup>b)</sup>	ALDOA	72C-2	VDAC		
241-8 24T-9"	TIMPI ST2	24C-4 <sup>a)</sup>	GUCATB	72C-3	NOO2		
24T-10 <sup>11</sup>	STYX	24C-5**)	ENO1	72C-5 <sup>lo</sup>	NMEL		
24T-11"	SETPO	24C-12 <sup>b)</sup>	GRB2	72C-6 <sup>13</sup>	TIMM8A	-	
48T-1 <sup>b1</sup>	SME2	24C-13 <sup>k)</sup>	HNRPA2BI	72C-0	HBGI	-	
48T-2 <sup>b1</sup>	DIC	24C-14 <sup>h)</sup>	HNRPA2BI	72C-8 <sup>lo</sup>	NPMI		
48T-8 <sup>b</sup> 1	HSPBI	24C-16 <sup>h)</sup>	PPIA	72C-8 72C-9 <sup>10</sup>	TIAFI		
48T-9 <sup>h</sup> '	TRIM3	24C-20 <sup>112</sup>	TIAFI	72C-9 72C-10 <sup>ai</sup>	ATOXI	-	
48T-13 <sup>b)</sup>	PGKI	48C-I <sup>b)</sup>	NMF2		RNASE8	-	
48T-14 <sup>b1</sup>	PRDX2	48C-2 <sup>b)</sup>	UBE203	72C-11 <sup>a)</sup>		-	
		10.0		— <u>72C-12<sup>bi</sup></u>	HSPEI	-	
				72C-13 <sup>™</sup>	TBCA		





# Hierarchical Clustering Analysis of Cyclic RGDinduced Protein Profile of MCF-7 cells





# **Gene Annotation**


- Gene Ontology Consortium
  - Biological Process
  - Cellular Component
  - Molecular Function
- BGSSJ *Microarrays: Methods and Protocols*, The humana press inc. (2007)
  - http://bgssj.sourceforge.net/
  - Automatic functional classification
  - JAVA application (requires J2RE 1.3)

















Apoptosis Regulator					
Description	Genebank accession No.	6 h Fold Change	24 h Fold Change	48 h Fold Change	72 h Fold Change
Group I	FY REL	15,000	fig. ( )		6 4 6 D
caspase 10, apoptosis-related cysteine protease	U60519			1	0.471
CASP8 and FADD-like apoptos:s regulator	U97075	57-10	100	T	0.355
nucleoside diphosphate kinase type 6 (inhibitor of p53-induced apoptosis-alpha)	AF051941	1			0.376
Group 2					
caspase 3, apoptosis-related cysteine protease	U13738	17.00	2.301	-	
CASP8 and FADD-like apoptos:s regulator	AF005775	X	2.272		V5 -
Group 3					
caspase 9, apoptosis related cysteine protease	U60521	-	-	2.519	- 1
Group 4					
caspase 4, apoptosis-related cysteine protease	Z48810	2.615	8-1-1-1	2.796	2.819
Group 5				BADIE TO	
inhibitor of apoptosis protein	AAF19819		170 - 1915		5.249
caspase 7, apoptosis-related cysteine protease	U67319	W 8 - 7 -	- 3		2.19
caspase 4, apoptosis-related cysteine protease	U28976	K Jack	10 Co.	10-20	2.603
Group 6	A CONTRACTOR	12 (2) 35	TIME!	2011111	Mill Control
CASP8 and FADD-like apoptos:s regulator	AF015450		A SECTION	00012	6.912









# Weights Matrix Apoptosis Regulator

Weights	Gene 1	Gene 2
2.670363	AF015450	U60521
2.068236	AAF19819	U60521
-1.889373	AF015450	AAF19819
-1.427408	AAF19819	AAF19819
-0.81632	AF005775	AF005775
-0.761848	U13738	AF005775
0.753277	AF015450	U60519
0.682257	U13738	AAF19819
0.646907	Z48810	AF005775
0.636552	AF015450	AF005775
0.632796	AF005775	Z48810
0.594627	AF005775	AAF19819
-0.55848	Z48810	AAF19819
0.543142	AAF 19819	U60519
-0.527872	U60521	U60521
0.518056	U28976	U60521
0.508007	U60521	AF005775
0.499483	U13738	Z48810






# Weights Matrix Signal Transducer

Weights	Gene1	Gene2
-0.875598	NM_003242	L27475
0.834468	M37435	L27476
-0.78655	L27475	L27477
-0.760695	M21188	L27478
-0.728793	D63395	L27479
0.645775	NM_003242	NM_005429
0.608239	NM_003242	NM_005430
0.558504	L27475	NM_005431
0.538674	D63395	NM_005432
0.530764	U72338	L27475
0.455149	AF041240	L27476
0.453129	AI634668	L27477
-0.452645	AB017364	L27478
0.449854	NM_003242	U12535
0.444301	M21188	AF251118
-0.442259	M37435	U52112
0.437687	M21188	U12535
0.429097	NM_003242	AF251118





# Gene Network Modeling and Reconstruction

BIOINFORMATICS APPLICATIONS NOTE Vol. 20 no. 18 2004, pages 3691-3693 doi:10.1093/bioinformatics/toh/428



# GeneNetwork: an interactive tool for reconstruction of genetic networks using microarray data

Chia-Chin Wu $^{\rm I}$  , Hsuan-Cheng Huang  $^{\rm I,2,*}$  , Hsueh-Fen Juan  $^{\rm 3,4}$  and Shui-Tein Chen  $^{\rm I,3,5,*}$ 

<sup>1</sup> Institute of Biological Chemistry and Genomics Research Center, Academis Shica, Tajeio, Takena, Tajeio, Takena, Tajeio, Tajeio,

Received on November 12, 2003; revised on April 29, 2004; accepted on July 5, 2004

### ABSTRACT

Summary: Inferring genetic network architecture from time series data generated from high Privagiput evegenmental technologies, such as CDNA microarray, can help us to under stand the system behavior of ining organisms. We have developed an interactive tool, Genefletwork, which provides approaches to left entitled tools, or the provides approaches to left entitled tools, and approaches to left entitled tools approached to left entitled tools, and approaches to left entitled tools and tools are the tools are the tools and tools are the tools and tools are the tools are the tools and tools are the tools are the tools are the tools and tools are the tools are

diagrams of interacting elements based on time-course gene expression data generated from cDNA microarray exper iments. The reconstructed genetic network can then by validated experimentally.


Because most genetic network models are mathematically and computationally complicated, a fill understanding of the and computationally complicated as fill understanding of the development of tools for the computational and vasual exploration of complete networks. Although several persoous attempts have been under to visualize patrivays from prox known knowledge and to similate system dynamic processes—in software packages (Bertikevatz et al., 2003). Dozes of the Dallquist et al., 2003; Samonte et al., 2003. Dozes of the allow users to infer greater networks from experimental processes, and the processes of the complex processes.


Bioinformatics (2004) 20: 3691-3.


# **GeneNetwork Software**


- Interactive interface for reconstructing gene network based on microarray data
- Reconstruction Model
  - Boolean Network
  - Baysian Network
  - Linear Model
  - S-System
- http://genenetwork.sbl.bc.sinica.edu.tw/


Bioinformatics (2004) 20: 3691-3











### Summary

- We have synthesized a novel cyclic-RGD peptide, which induces apoptosis of MCF-7
- These results provide a molecular explanation for the properties of cRGD in breast cancer cells and present a valuable in-depth description of their possible impact on breast cancer therapy


### **Drug Discovery:**

ATP synthase, a new target for cancer therapy

75


## Rank of deaths from leading causes of death in 2007

Rank	Causes of death
1	Malignant neoplasms
2	Heart disease
3	Cerebrovascular disease
4	Diabetes mellitus
5	Accidents and adverse effects
6	Pneumonia
7	Chronic liver disease and cirrhosis
8	Nephritis, nephrotic syndrome and nephrosis
9	Suicide
10	Hypertensive disease
	Statistics data, Department of Health, Executive Tuan, Taiwan. 200



### **Breast cancer**

- The most common malignancy among women in developed regions of the world.
- In the United States, more than 200,000 women are diagnosed with breast cancer each year and nearly 41,000 patients die.
- Although breast cancer is primarily a disease of women, about 1% of breast cancers occur in men.
- stages of breast cancer:




Harris JR. Staging and natural history of breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds Diseases of the Breast, 2nd edition. Philadelphia: Lippincott, Williams and Wilkins, 2000: 403-424.

Cserni G, Kulka J. [New TNM classification of breast tumors]. Orv Hetil. 2003 Aug 10:144(32):1563-8

### **Cancer Robustness**

 Viewing cancer as a robust system with potential points of fragility opens up new strategies for the development of drugs and therapies.



NATURE 2003, 426, 125.

Hunt for fragility: weaknesses in tumor growth dynamics could yield new anti-cancer therapies.

### **Targeting Therapy**

 Drugs or other substances which identify and attack specific cancer cells without harming normal cells.





### Goal


 To discover drug targets and antitumor agents.


81


# How Proteomics can help drug development FINDING NEW DRUG TARGETS [Here, devising a drug to kill the skin cancer melanoms] TWO OMENGOMAL GELS TOWN OMENGOMAL GELS TOWN OMENGOMAL GELS TOWN OF THE PROTEIN LOCATION FOR T













## The Expression Levels of ATP Synthase $\beta$ Subunit


2DE










The expressions of ATP synthase  $\boldsymbol{\beta}$  subunit in tumor tissues are higher than normal tissues.











### The function of the rotary electromotor

 Torque generation by Brownian rotary motion and directed ion flow



**ATP** 

Nature 459, 364-370 (21 May 2009)




# Characterization of ATP synthase expressed on MCF-7 cell surface (A) (B) (B) (B) (B) (A) (Confocal microscopy image of the distribution of ATP synthase subunit on MCF-7 cell surface. MCF-7 were fix and with (lower)/without (upper) permeabilization. Red, ATP synthase subunit; blue, hoechst 33342. (B) Cells in red area represent the ones stained with anti-ATP synthase subunit Ab followed by FITC-labeled anti-mouse IgG antibodies. Cells in black area denote negative control cells.

J Proteome Research 2008

# Molecular modeling of the inhibition on ATP synthase Homology modeling and protein-ligand docking simulation Sequence alignment

## Homology modeling of human ATP synthase using bovine as the template



The sequence identity between human and bovine ATP synthase is 99%. We used MODELER program encoded in InsightII and used bovine ATP synthase which has the 3D structure as the template to model human ATP synthase. The structure with the lowest energy scores was chosen as the candidate.


97

# Three potent drugs were screened out by protein-ligand docking simulation

Aurovertin B


Resveratrol

Piceatannol




Docking simulation was done by the shape-based docking algorithm LigandFit. All calculations were carried out in the Discovery Studio 1.2.

Aurovertin B can dock into ATP synthase  $\beta$  subunit. J Proteome Research 2008



# Effects of ATP synthase inhibitors on cell viability in MCF-7 breast cancer cells





When treated with ATP synthase inhibitor, aurovertin B, breast cancer cells exhibited a significant decrease in cell density.


Aurovetin B inhibited the growth of MCF-7 cells in a dose-dependent manner. The  $\rm IC_{50}$  is 0.1 um.


10:

# Effects of aurovertin B on cell viability in breast normal cells (MCF-10A) and cancer cells *in vitro*MCF-10A (no significant cytotoxicity) MCF-7 (IC<sub>50</sub>: 0.89) MCF-7 (IC<sub>50</sub>: 0.09) The invasion capacity MCF-10A T-47D MCF-7 MDA-MB-231












# Characterization of aurovertin B induced cell death in human MCF-7 cells Control Aurovertin B Morphology DAPI staining Phase contrast microscopy shows cell shrinkage, irregularity in shape, and cellular detachment in aurovertin B-treated cells. MCF-7 cells stained with 4, 6-diamidino-2-phenylindole (DAPI). Condensation and

shrinkage of nuclei in aurovertin B-treated cells







### **Summary**

- ATP synthase was upregulated in cancerous tissues and expressed on the surface of cancer cells.
- ATP synthase inhibitor aurovertin B could target on the cancer cells and leave normal unharmful.
- Aurovertin B inhibits proliferation of breast cancer cells by inducing apoptosis and arresting cell cycle at the G0/G1 phase.
- ATP synthase can be a good novel therapeutic target.

### Mechanism study:

Systems analysis reveals the antileukemia molecular mechanism induced by *Ganoderma lucidum* polysaccharides

# Outline Introduction Cell Death Cell Differentiation Summary Outline Introduction Cell Differentiation Cell Company Available The Company Availabl

### **INTRODUCTION**

115

### Ganoderma lucidum (Reishi)




 Ganoderma lucidum has been widely used as an herbal medicine for promoting health and longevity in China and other Asian countries.

Bioorg. Med. Chem. 10, 1057-1062 (2002).

 Polysaccharide extracts from Ganoderma lucidum has been reported to exhibit immunomodulating and anti-tumor activities.

Bioorg. Med. Chem. 12, 5595-5601 (2004).

 F3
 President Wong's group purified the active components of the polysaccharide extracts by gel filtration chromatography and designated it as F3.




Bioorg. Med. Chem. 10, 1057-1062 (2002).

117

### Reishi Polysaccharides

The major carbohydrate components in F3 are glucose, mannose and galactose.



Sugar Components of F3	Percentage (%)				
D-Glucose	58.1				
D-Mannose	15.1				
D-Galactose	13.5				
L-Fucose	7.1				
D-Xylose	3.1				
D-N-acetylglucosamine	1.2				
L-Rhamnose	0.7				
D-N-acetylglucosamine	1.2				


Bioorg. Med. Chem. 10, 1057-1062 (2002).

### Goal

- How can F3 stimulate anti-tumor effects on cancer cells?
- To understand the molecular mechanism underlying the F3 exertion in THP-1 cells


119


### **CELL DEATH**





### Microarray


- A powerful approach to accurately measure changes in global mRNA expression levels.
- Used to
  - Discover novel genes
  - Determine gene functions
  - Evaluate drugs
  - Dissect pathways
  - Classify clinical samples.














# Search for Significantly Disturbed Biological Pathways

 Statistical methods based on Fisher's exact test and false discovery rate.

Nucleic Acids Research, 2004, Vol. 32,W460-464









### Comparison: F3 Treatment for 6 and 24 Hrs


- ArrayXPath
  - Induction of apoptosis through DR3 and DR4/5 death receptors
  - NF-κB signaling pathway
  - TNFR2 signaling pathway
- IPA
  - Death receptor signaling
  - IL-10 signaling
  - Interferon signaling
  - IL-6 signaling
  - Apoptosis signaling


131


## Induction of Apoptosis through DR3 and DR4/5 Death Receptors











### **GeneNetwork Software**


- Interactive interface for reconstructing gene network based on microarray or proteomics data
- Reconstruction Model
  - Boolean Network
  - Baysian Network
  - Linear Model
  - Simplified S-System


### S-system Formalism


 Dynamics of biological systems can be described mathematically by S-System

$$\dot{\mathbf{X}} = \mathbf{f}(\mathbf{X}, \mathbf{p}) = \begin{bmatrix} \alpha_1 \prod_{j=1}^{n+m} X_j^{g_{1j}} - \beta_1 \prod_{j=1}^{n+m} X_j^{h_{1j}} \\ \vdots \\ \alpha_n \prod_{j=1}^{n+m} X_j^{g_{nj}} - \beta_n \prod_{j=1}^{n+m} X_j^{h_{nj}} \end{bmatrix}, \mathbf{X}(0) = \mathbf{X_0}$$


Bioinformatics, 2005, 7, 1180-8.









### **CELL DIFFERENTIATION**






### Macrophage and Superoxide

 Superoxide and NO are toxic radicals produced by macrophages to kill microorganisms upon infections.




# NBT Reduction Assay Superoxide anion was generated by xanthine-

- xanthine oxidase and detected by the NBT reduction.
- NBT (nitroblue tetrazolium) is a reagent that can absorb superoxide and change it color to purple (absorbed at 570nm).
- The soluble yellow form of NBT was reduced by superoxide to form insoluble, blue formazan precipitates.



- in F3-treated THP-1 cells.
- F3 treatment was able to increase NBT reduction significantly and might induced differentiation of THP-1 cells into macrophages.




### Macrophage Differentiation Markers

- Macrophage differentiation is associated with increased expression of several genes, which are critical for the functionality of macrophage.
- CD11b, CD14, CD68, MPO, and MMP9 are classical markers of macrophage differentiation.

  Aordet 0. et al. Blood 15: 4446-53 (2002).
  Ding Q. et al. J. Leukoc. Biol. 81: 1568-76 (2007).

149

### Macrophage Cell Markers CD11b, CD14, and CD68 are classical markers of macrophage differentiation. 12 6 Hrs 10 Fold Change (-AACt) ■ 12 Hrs 8 ■ 24 Hrs 6 ■ 48 Hrs 4 2 CD14 CD11b -2



### MPO: Myeloperoxidase

- MPO is present in the granule, which is a major component of lysosome.
- The enzyme MPO is synthesized only in granulocytes and monocytic cells, making it an important marker of myeloid lineage.
- Decrease in the activity of MPO is a characteristic feature observed as monocytic cells differentiate into macrophages.

Koeffler H. P. et al. *J. Clin. Invest.* 66:1101-8 (1980). Lin K.M. et al. *Leukemia*. 16:1143-53 (2002). 152 Shiney S. J. et al. *Mol Cel Biochem*. 233: 9-17 (2002).

### MMP-9: Matrix Metalloproteinase-9

- MMP-9, a Zn<sup>2+</sup>-dependent secreted type IV collagenase, can degrade extracellular mactrix components such as collagnes and elastins.
- MMP-9 expression increases as blood monocytes differentiate into macrophages.

Michael H. et al. *Biol Chem.* 387:69-78 (2006) Nicole. L. W. et al. *J. Leuko Biolo.* 80:1052-66 (2507)

### Macrophage Specific Enzyme

 F3-induced macrophage differentiation is associated with increased expression of CD11b, CD14, and CD68, while intracellular MPO decreased.

F3 Treatment Hrs

 F3-induced macrophage differentiation is associated with slightly increased expression of MMP-9, an important mediator of macrophage chemotactic activity.

MMP-9  $\Delta$ Ct  $\pm$  S.D


			6		$15.2 \pm 0.1$		22.48	3 ± 0	.1			
			12		$17.83 \pm 0.98$	3	19.83 ± 1.12					
		24			$16.66 \pm 0.5$		$17.9 \pm 0.53$					
	48				16.1 ± 0.15		14.83 ± 0.47					
F3 30	μg/n	nl Trea	atmer	nt (Hrs)		F	3 30	μ <b>g/m</b>	nl Trea	atmer	nt (Hrs)	)
0	6	12	24	48			0	6	12	24	48	
PO	4 600	-	60%	***	[mDNA]	MMP9		-	1000	-	-	
ctin		•	-	-	[IIIKIVA]	$\beta$ -actin			-		1	
MPO	-100	-	-			MMP9	- 4	-	-		_	
					[Protein]	020101000000 <b>2</b> 001			-	_		15
	PO Catin MPO	0 6 PO actin	0 6 12 PO ectin	12 24 48 F3 30 μg/ml Treatmen 0 6 12 24 PO	12 24 48  F3 30 μg/ml Treatment (Hrs) 0 6 12 24 48  PO exctin	12 17.83 ± 0.98 24 16.66 ± 0.5 48 16.1 ± 0.15  F3 30 μg/ml Treatment (Hrs) 0 6 12 24 48  PO cetin [mRNA]	12 17.83 ± 0.98 24 16.66 ± 0.5 48 16.1 ± 0.15  F3 30 μg/ml Treatment (Hrs) 0 6 12 24 48  PO ctin MPO (Protein)  (Protein)	12 17.83 ± 0.98 19.83 24 16.66 ± 0.5 17.9 48 16.1 ± 0.15 14.83 16.1 ± 0.15 14.83	12 17.83 ± 0.98 19.83 ± 1.  24 16.66 ± 0.5 17.9 ± 0.5  48 16.1 ± 0.15 14.83 ± 0.  F3 30 μg/ml Treatment (Hrs)  0 6 12 24 48  PO  cctin  MPO  (Protein)	12 17.83 ± 0.98 19.83 ± 1.12 24 16.66 ± 0.5 17.9 ± 0.53 48 16.1 ± 0.15 14.83 ± 0.47  F3 30 μg/ml Treatment (Hrs) 0 6 12 24 48  PO (ctin	12 17.83 ± 0.98 19.83 ± 1.12 24 16.66 ± 0.5 17.9 ± 0.53 48 16.1 ± 0.15 14.83 ± 0.47  F3 30 μg/ml Treatment (Hrs) 0 6 12 24 48  PO (ctin)  MPO (Protein)  19.83 ± 1.12 17.9 ± 0.53 14.83 ± 0.47  F3 30 μg/ml Treatmen 0 6 12 24  MMP9  (Protein)	12 17.83 ± 0.98 19.83 ± 1.12 24 16.66 ± 0.5 17.9 ± 0.53 48 16.1 ± 0.15 14.83 ± 0.47  F3 30 μg/ml Treatment (Hrs) 0 6 12 24 48  PO 1ctin MPO MMP9 β-actin MMP9

MPO  $\Delta$ Ct  $\pm$  S.D

 $15.5 \pm 0.99$ 

## Specific Involvement of Caspases in Differentiation into Macrophages

- Alteration of this pathway might account for the accumulation of monocytes in the bone marrow and lead to leukemia formation.
- Differentiation-associated caspase activation is highly specific of the cell type.




Nathalie Droin et al. *Biochimie* 1:1-7 (2007) Olivier S. et al. *Blood* 15: 4446-53 (2002).


155

### p53 Family

- The role of p53 as a tumor suppressor is generally attributed to its ability to stop the proliferation by inducing cell cycle arrest or apoptosis.
- The p53 also have essential functions in differentiation control.




Thurston S. Nature Rev. Cancer 7:165-168 (2957)




### Caspase Inhibitor: Z-VAD-FMK

 The general caspase inhibitor, Z-VAD-FMK, prevented the differentiation of F3-induced THP-1 cells into macrophages in a dose-dependent manner and blocked the appearance of CD11b and CD14 on their plasma membrane.



### Regulation of Differentiation into Macrophage: Caspase Cleavage Inhibitor: Z-VAD-FMK The caspase cleavage is specifically involved in

the macrophage differentiation process.



### p53 Inhibitor: Pifithrin- $\alpha$

The p53 inhibitor, pifithrin- $\alpha$ , also prevented the differentiation of F3-induced THP-1 cells into macrophages in a dose-dependent manner and blocked the appearance of CD11b and CD14 on their plasma membrane.

